Key Takeaways
- Q1 adjusted EPS reached $10.31 per share, surpassing analyst expectations of $10.19–$10.20
- Shares tumbled as much as 7.4% in early trading following the earnings announcement
- Company maintained full-year adjusted EPS guidance at $9 while reducing reported profit target to $8.36 from $8.89
- Medicare Advantage Star Ratings decline for 2026 continues to pressure bonus revenue and bottom-line results
- Leadership highlighted widening gap between healthcare expenditures and federal reimbursement rates
Humana delivered first-quarter results that exceeded Wall Street expectations on Wednesday, yet the market response was decidedly negative. Shares plunged as much as 7.4% during premarket hours after the health insurance giant maintained its annual earnings projection while competitors upgraded their forecasts.
The company reported adjusted earnings of $10.31 per share, surpassing analyst projections that ranged from $10.19 to $10.20. Total revenue climbed to $39.65 billion from $32.11 billion in the prior-year period, exceeding consensus estimates of $39.37 billion.
Despite these solid numbers, investor enthusiasm remained subdued.
Morningstar’s Julie Utterback suggested that market participants had anticipated an upward revision to annual guidance following such a robust quarterly performance. The expected increase never materialized.
Management affirmed its full-year adjusted earnings projection of at least $9 per share. Meanwhile, the reported earnings outlook saw a downward revision to at least $8.36 per share from the earlier target of at least $8.89.
This adjustment accounts for expenses associated with a comprehensive transformation initiative, encompassing workforce reduction costs, write-downs on assets, and fees paid to external advisors.
Star Ratings Create Headwinds for Profitability
Central to the current challenges are Humana’s diminished Medicare Advantage Star Ratings for 2026. These performance metrics, ranging from one to five stars, directly influence bonus payments received from federal authorities. Diminished ratings translate to reduced bonus compensation.
Company executives have consistently highlighted this challenge in recent quarters. First-quarter net income registered at $9.83 per share, declining from $10.30 in the corresponding period last year — a clear indication of ongoing rating pressures.
Chief Executive Jim Rechtin indicated that healthcare utilization patterns and associated costs aligned with internal projections. However, he acknowledged that the differential between care delivery expenses and government reimbursements has expanded year-over-year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Insurance Segment Delivers Positive Benefit Ratio
Amid the challenges, Humana’s insurance division reported a benefit ratio of 89.4% for the first quarter — the proportion of premium income allocated to medical expenses. This figure came in favorable to the company’s own projection of just under 90% and beat Wall Street’s 89.7% consensus.
Lower ratios indicate superior operational performance for insurers. Readings beneath 90% typically signal effective cost management.
Looking toward Q2, Humana anticipates this metric will increase to slightly above 91%, pointing to upcoming cost challenges.
The organization also observed that overall medical service and pharmaceutical cost trajectories are performing marginally better than anticipated, which Cantor’s Sarah James identified as among the limited positive elements in the report.
James raised red flags despite this silver lining. “HUM has several signals that the back-half of the year could be difficult to manage,” she said, calling the premarket reaction “a warning sign.”
Humana indicated it will modify benefit structures where necessary to maintain margin stability. Federal authorities announced earlier this month that Medicare Advantage payment rates would increase by an average of 2.48% for 2027.
Shares traded down approximately 2% in premarket activity after the initial 7.4% decline.
